Table 1.
Clinical Data and CSF1R mRNA Expression in Colon Cancer Cases From 2 Independent Patient Cohorts
| Characteristic | TCGA-COAD |
GSE39582 |
||||||
|---|---|---|---|---|---|---|---|---|
| Total |
CSF1R |
P | Total |
CSF1R |
P | |||
| Low | High | Low | High | |||||
| All patients | 440 (100.0) | 335 (76.1) | 105 (23.9) | 566 (100.0) | 532 (76.1) | 34 (23.9) | ||
| Age | ||||||||
| <median | 206 (46.9) | 164 (79.6) | 42 (20.4) | .109 | 283 (51.2) | 272 (96.1) | 11 (3.9) | .033a |
| ≥median | 234 (53.1) | 171 (73.1) | 63 (26.9) | 282 (48.8) | 259 (91.8) | 23 (8.2) | ||
| Sex | ||||||||
| Male | 235 (53.4) | 182 (77.4) | 53 (22.6) | .490 | 310 (54.8) | 290 (93.5) | 20 (6.5) | .624 |
| Female | 205 (46.6) | 153 (74.6) | 52 (25.4) | 256 (45.2) | 242 (94.5) | 14 (5.5) | ||
| UICC stage | ||||||||
| I | 73 (17.0) | 58 (79.5) | 15 (20.5) | .378 | 33 (5.9) | 33 (100) | 0 (0) | .497 |
| II | 169 (39.4) | 122 (72.2) | 47 (27.8) | 264 (47.0) | 248 (93.9) | 16 (6.1) | ||
| III | 126 (29.4) | 97 (77.0) | 29 (23.0) | 205 (36.5) | 191 (93.2) | 14 (6.8) | ||
| IV | 61 (14.2) | 50 (82.0) | 11 (18.0) | 60 (10.7) | 56 (93.3) | 4 (6.7) | ||
| MSI status | ||||||||
| MSS/MSI-low | 323 (81.2) | 253 (78.3) | 70 (21.7) | .005a | 444 (85.5) | 424 (95.5) | 20 (4.5) | .029 |
| MSI-high | 75 (18.8) | 47 (62.7) | 28 (37.3) | 75 (14.5) | 67 (89.3) | 8 (10.7) | ||
| CMS subtype | ||||||||
| CMS1–3 | 253 (73.3) | 219 (86.6) | 34 (13.4) | <.0001a | 360 (73.9) | 351 (97.5) | 9 (2.5) | <.0001a |
| CMS4 | 92 (26.7) | 41 (44.6) | 51 (55.4) | 127 (26.1) | 107 (84.3) | 20 (15.7) | ||
| CRIS subtype | ||||||||
| CRIS-A/C–E | 283 (87.9) | 219 (77.4) | 64 (22.6) | .002a | 488 (86.2) | 468 (95.9) | 20 (4.1) | <.0001a |
| CRIS-B | 39 (12.1) | 21 (53.8) | 18 (46.2) | 78 (13.8) | 64 (82.1) | 14 (17.9) | ||
Values are n (%).
Percentage values are given in parentheses. Association of CSF1R expression with clinical parameters was analyzed using chi-square tests. CSF1R low or high status was defined according to Figures 1A and 1B, respectively.
CMS, consensus molecular subtype; COAD, colon adenocarcinoma; CRIS, colorectal cancer intrinsic subtypes; MSI, microsatellite instability; UICC, Union for International Cancer Control; TCGA, The Cancer Genome Atlas.
a
P < .05.